20 likes | 111 Views
This study analyzes pain and sleep scores at the end of a randomized treatment phase using CBD/THC at a 1:1 ratio versus placebo. The results, presented by Rog et al. in Neurology 2005, highlight significant improvements in pain and sleep for participants. The baseline pain and sleep scales range from no pain/disruption to severe pain/sleep disturbances. The study involved 34 participants with clear distinctions between the active and placebo groups.
E N D
Pain scores at end of randomized treatment phase 7.00 P=0.005* 6.00 N=34 N=32 5.00 N=32 4.00 Mean NRS-11 pain score N=32 3.00 2.00 1.00 0.00 Baseline On treatment Scale 0 = No pain 10 = Worst possible pain CBD/THC 1:1 Placebo *Active vs placebo Rog et al. Neurology 2005;65:812-9. Presented at CMSC 2007.
Sleep scores at end of randomized treatment phase 6.00 5.00 P=0.003* N=34 4.00 N=32 N=32 Mean NRS-11 sleep score 3.00 N=32 2.00 1.00 0.00 Baseline On treatment Scale 0 = Did not disrupt sleep 10 = Completely disrupts sleep, unable to sleep due to pain CBD/THC 1:1 Placebo *Active vs placebo Rog et al. Neurology 2005;65:812-9. Presented at CMSC 2007.